Provided by Tiger Trade Technology Pte. Ltd.

Jasper Therapeutics

0.7114
+0.01171.67%
Post-market: 0.6972-0.0142-2.00%19:44 EDT
Volume:388.05K
Turnover:271.81K
Market Cap:23.67M
PE:-0.76
High:0.7400
Open:0.7149
Low:0.6545
Close:0.6997
52wk High:2.87
52wk Low:0.3151
Shares:33.27M
Float Shares:30.00M
Volume Ratio:1.39
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9300
EPS(LYR):-3.9545
ROE:-255.05%
ROA:-113.41%
PB:16.75
PE(LYR):-0.18

Loading ...

Jasper Therapeutics director Christian Nolet resigns from board

Reuters
·
May 22

Jasper Therapeutics Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
May 15

Jasper Therapeutics price target lowered to $3 from $4 at RBC Capital

TIPRANKS
·
May 15

TD Cowen Downgrades Jasper Therapeutics to Hold From Buy

MT Newswires Live
·
May 15

Jasper Therapeutics Inc : TD Cowen Cuts to Hold From Buy

THOMSON REUTERS
·
May 15

Jasper Therapeutics downgraded to Hold from Buy at TD Cowen

TIPRANKS
·
May 15

Jasper Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15

Jasper Therapeutics Q1 net loss narrows 94% to $1.17 million

Reuters
·
May 15

Jasper Therapeutics Q1 Net Income USD -1.2 Million

THOMSON REUTERS
·
May 15

Jasper Therapeutics Q1 EPS USD -0.04

THOMSON REUTERS
·
May 15

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
May 15

Jasper Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
May 08

Jasper Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Apr 02

Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI

TIPRANKS
·
Apr 01

Jasper Therapeutics Q4 EPS $(0.32) Beats $(0.64) Estimate

Benzinga Earnings
·
Mar 31

Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)

TIPRANKS
·
Mar 31

Jasper Therapeutics Q4 EPS USD -0.32

THOMSON REUTERS
·
Mar 31

Jasper Therapeutics FY25 net loss narrows to $75.8 million; cash drops to $28.7 million

Reuters
·
Mar 31

Press Release: Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Mar 31

Jasper Therapeutics Inc : UBS Assumes Coverage With Neutral Rating; Target Price $1.5

THOMSON REUTERS
·
Mar 23